Westlake Village dermatology therapy startup Arcutis announced a $94.5 million capital raise Oct. 21 to fund Phase 3 clinical development for its topical plaque psoriasis treatment. The financing round was led by HBM Healthcare Investments and included funding from Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures and Goldman Sachs. Returning investors also contributed to the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
